Subsequent supplements added adolescent obesity (12 years), refined titration guidance, and updated safety sections as more postmarketing data accrued
Some diabetes medications, including sulfonylureas and insulin, may interact with GLP-1 medications and increase the risk of hypoglycemia
By equipping readers with practical advice and insights, this article aims to improve the overall health and well-being of those using semaglutide
The Evaluate Renal Function With Semaglutide Once Weekly (FLOW) trial is the first dedicated kidney outcome study specifically designed to assess the effect of a GLP-1 receptor agonist (once-weekly subcutaneous semaglutide) in people with type 2 diabetes mellitus and CKD at high-risk of progression (Table 1, Fig
Cons: It may be a little difficult for those with larger thighs or mobility problems
Hormonal changes particularly declining oestrogen can affect where fat is stored, how the body regulates appetite and insulin sensitivity, and how easily muscle mass is maintained